Journal: International journal of colorectal disease
Article Title: A trial of radiofrequency ablation for anal intraepithelial neoplasia.
PMID/MRN: 27770248
Publication Date: 2016-Oct-21
Abstract:
Radiofrequency ablation (RFA) effectively treats esophageal high-grade dysplasia, but its efficacy in treating anal canal high-grade squamous intraepithelial lesions (HSILs) is unsubstantiated. This prospective study assessed the safety and efficacy of applying hemi-circumferential RFA to anal canal HSIL.
Twenty-one HIV-negative participants with HSIL occupying ²Êhalf the anal canal circumference were treated with hemi-circumferential anal canal RFA. Participants were assessed every 3Êmonths for 12Êmonths with high-resolution anoscopy; recurrence in the treatment zone was re-treated with focal RFA.
Twenty-one participants with a mean of 1.7 lesions (range 1-4) enrolled and completed the trial. Six (29Ê%) participants had recurrent HSIL within the treated hemi-circumference within 1Êyear. Four participants (19Ê%) had persistence of an index lesion at 3Êmonths. One (2.9Ê%) index HSIL persisted again at 12Êmonths. No participants had more than two RFA treatments. KM curve-predicted HSIL-free survival within the treatment zone at 1Êyear was 76Ê% (95Ê% CI 52-89Ê%). Comparing the first 7 and last 14 participants, the predicted 1-year HSIL-free survivals are 43Ê% (95Ê% CI 10-73Ê%) and 93Ê% (95Ê% CI 59-99Ê%), respectively (pÊ=Ê0.008), suggesting a learning curve with the treating physician. Multivariable analysis showed decreased recurrence in the last 14 participants (HR 0.02; 95Ê% CI 0.001-0.63) while increasing BMI increased recurrence (HR 1.43, 95Ê% CI 1.01-2.01). No participants had device or procedure-related serious adverse events, anal stricture, or heavy bleeding.
Hemi-circumferential RFA yielded a high rate of anal HSIL eradication in HIV-negative patients at 1Êyear with minimal adverse events. Lesion persistence was probably related to incomplete initial ablation.